Literature DB >> 10728680

Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.

Z Ni1, W Lou, E S Leman, A C Gao.   

Abstract

Overexpression of interleukin 6, a downstream target of the GBX2 homeobox gene, has been linked to the progression of prostate cancer. The Janus kinase-signal transducers and activators of transcription signaling pathway transmits interleukin 6-mediated signals from cell surface receptors to the target genes in the nucleus and is critical in mediating cellular growth and differentiation. We demonstrate that cells derived from both rat and human prostate cancers have constitutively activated Stat3, with Stat3 activation being correlated with malignant potential. Blockade of activated Stat3 by ectopic expression of a dominant-negative Stat3 in human prostate cancer cells significantly suppresses their growth in vitro and their tumorigenicity in vivo. Furthermore, the Janus kinase inhibitor, tyrphostin AG490, inhibited the constitutive activation of Stat3 and suppressed the growth of human prostate cancer cells. These results indicate that activation of Stat3 signaling is essential in the progression of prostate cancer cells and suggest that targeting Stat3 signaling may yield a potential therapeutic intervention for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728680

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

Review 1.  Protein kinases as therapeutic targets.

Authors:  R Sridhar; O Hanson-Painton; D R Cooper
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer.

Authors:  Jennifer Dien; Hesham M Amin; Neil Chiu; Winson Wong; Christine Frantz; Brian Chiu; John R Mackey; Raymond Lai
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis.

Authors:  Lisa Pham; Lisa Christadore; Scott Schaus; Eric D Kolaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

4.  Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells.

Authors:  Sung-Lyul Lim; Sang-Yoon Park; Sukmin Kang; Dain Park; Sung-Hoon Kim; Jae-Young Um; Hyeung-Jin Jang; Jun-Hee Lee; Chul-Ho Jeong; Jung-Hee Jang; Kwang Seok Ahn; Seok-Geun Lee
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

5.  Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Soo Ok Lee; Xin Lin; Donald L Trump; Allen C Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

6.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.

Authors:  Jae Yeon Chun; Yan Hu; Elaine Pinder; Jianguo Wu; Fengzhi Li; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

7.  Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.

Authors:  Rana P Singh; Komal Raina; Gagan Deep; Daniel Chan; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.

Authors:  Belen Elguero; Geraldine Gueron; Jimena Giudice; Martin A Toscani; Paola De Luca; Florencia Zalazar; Federico Coluccio-Leskow; Roberto Meiss; Nora Navone; Adriana De Siervi; Elba Vazquez
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

9.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

10.  Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells.

Authors:  H Siavash; N G Nikitakis; J J Sauk
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.